Trial Profile

A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of PBI-410 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BHV 1510 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Biohaven Therapeutics; Pyramid Biosciences

Most Recent Events

17 Nov 2025 Planned number of patients changed from 280 to 500.
28 May 2025 According to Biohaven Therapeutics media release, the preliminary results from this trial were presented at the Biohaven's 2025 R&D Day.
28 May 2025 Results presented in the Biohaven Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com